Noubar Afeyan Net Worth

Noubar Afeyan has an estimated net worth of $2.3 billion, according to Forbes Real-Time Billionaires, Noubar Afeyan profile (figures as of October 20, 2026). That is up from $1.9 billion in 2021.

Noubar Afeyan is a biotech entrepreneur in the healthcare industry. He founded and leads Flagship Pioneering, a life sciences innovation firm in Cambridge, Mass. He is also chairman and cofounder of Moderna. Moderna became widely known for its Covid-19 vaccine, which the U.S. FDA authorized in December 2020. Across his career, Afeyan has helped start more than 70 public and private healthcare and life sciences companies.

His wealth comes from building biotech businesses and holding stakes in them. Beyond Moderna, he owns shares in several publicly traded biotech companies in the U.S. He also spent years teaching entrepreneurship and management, serving at MIT's Sloan School of Management from 2000 to 2016 and later as a lecturer at Harvard Business School until 2020. Forbes put his net worth at $2.3 billion on its real-time billionaires tracker as of October 20, 2026.

How Noubar Afeyan built his fortune

Afeyan made his name by creating and backing biotech companies. His main business base is Flagship Pioneering, the Cambridge, Mass. firm he founded and now runs as CEO. Through that work, he has helped launch more than 70 healthcare and life sciences companies in both the public and private markets. That kind of repeated company building is the core of how he became wealthy and why he stands out in biotech.

A second major piece is Moderna, which he cofounded and chairs. The company became especially prominent after its Covid-19 vaccine won U.S. FDA authorization in December 2020. Forbes also notes that his holdings go beyond Moderna. He owns shares in several publicly traded biotech companies in the U.S., so his wealth is tied to a broader group of life sciences businesses, not just one company.

Forbes net worth changes over time

Forbes estimated Afeyan's fortune at $1.9 billion in 2021, then $1.7 billion in 2022, $1.6 billion in 2023, $1.4 billion in 2024, and $1.2 billion in 2025. On the 2026 World's Billionaires List, Forbes moved that figure back to $1.9 billion. Those shifts fit with a portfolio built around biotech stakes, including Moderna and other publicly traded healthcare companies in the U.S.

By October 2026, Forbes' real-time billionaires tracker placed him at $2.3 billion. That later figure points to the market value of his biotech holdings as the key driver. His money is connected to equity in Moderna, his position at Flagship Pioneering, and shares in other U.S. biotech companies. In short, changes in biotech company values appear to have a big effect on the Forbes estimate.